<DOC>
	<DOCNO>NCT00133146</DOCNO>
	<brief_summary>Allergen-specific immunotherapy ( SIT ) , administration gradually increase quantity allergen extract allergic patient , curative approach directly treat underlie allergic disease . GrassMATAMPL develop provide pre-seasonal specific immunotherapy patient allergy grass rye pollen ( hay fever ) . The tolerability immunogenicity GrassMATA ( allergen modify glutaraldehyde adsorbed tyrosine ) without MPL adjuvant ( monophosphoryl lipid A , extract bacterial cell surface ) investigate double-blind , randomized Phase IIa study volunteer allergic grass rye pollen . Additionally , study assess residual allergenicity modify grass rye pollen product GrassMATAMPL use skin prick test volunteer allergic grass rye pollen .</brief_summary>
	<brief_title>Assessment Contribution Monophosphoryl Lipid A ( MPL ) Grass Pollen Allergy Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<mesh_term>Monophosphoryl lipid A</mesh_term>
	<criteria>Patients must positive skin prick test grass rye allergen Specific IgE grass rye class &gt; = 2 History least 1 season moderate severe seasonal rhinoconjunctivitis due IgEmediated allergy pollen grass rye Males nonpregnant , nonlactating female postmenopausal naturally surgically sterile . Females childbearing potential confirm absence pregnancy accord negative urine pregnancy test must use acceptable birth control method Acute subacute atopic dermatitis and/or urticaria factitia and/or urticaria due physical chemical influence and/or chronic dermatitis Patient moderate severe asthma . Visual inspection forearm indicate potential problem conduct interpretation skin prick test ; forearm must available test History presence diabetes , cancer clinically significant cardiac , metabolic renal , hematologic disease disorder Recent clinically significant history ( within 2 year ) hepatic gastrointestinal , dermatologic , venereal , neurologic psychiatric disease disorder Any clinically significant ( determined investigator ) abnormal laboratory value Visit 0 Perennial allergen : clinically relevant sensitivity house dust mite ( Dermatophagoides pteronyssinus , Dermatophagoides farinae ) , mold ( Cladosporium cladosporoides , Alternaria alternata , Penicillium chrysogenum , Aspergillus fumigatus ) epithelium ( cat [ Felis domesticus ] , dog [ Canis familiaris ] ) Patient clinically relevant sensitivity follow summer/autumn season flower plant : Plantago lanceolata ( plantain ) , Atriplex sp . ( orache ) , Urtica dioica ( nettle ) , Artemisia vulgaris ( mugwort ) , Cynodon dactylon ( Bermuda grass ) , Ambrosia elatior ( ragweed ) . Secondary alteration affect organ ( i.e . emphysema , bronchiectasis ) History autoimmune disease and/or rheumatoid disease Patients take bblockers indication Patients allow receive adrenalin Patients tyrosine metabolism disturb Presence disease pathogenesis interfere immune response patient receive medication could influence result study Documented evidence acute significant chronic infection History anaphylaxis History angioedema Hypersensitivity excipients study medication Previous current hyposensitization therapy comparable grass allergen extract Currently use antiallergy medication drug antihistaminic activity Patient pregnant planning pregnancy and/or lactate Patient receive treatment preparation contain monophosphoryl lipid A past 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Specific Immunotherapy</keyword>
</DOC>